Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. RIC Transplant Using Haplo Donors

    ... -mismatched first-degree relatives utilizing PBSC as the stem cell source. The primary objective of the study is to estimate the ... failed to respond adequately to conventional-dose therapy or autologous transplantation Myeloproliferative diseases (myelofibrosis, ...

    Clinical Trial last updated 04/29/2016 - 10:52am.

  2. Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

    ... CD34+ selected, T-cell depleted allogeneic hematopoietic stem cell transplantation is indicated such as: AML in 1st remission - ... following a 1st remission who are not candidates for autologous transplants. any NHL in remission which is considered not ...

    Clinical Trial last updated 04/29/2016 - 1:59pm.

  3. Nonmyeloablative Haploidentical Transplant Followed by MLN9708

    ... reconstitution following haploidentical peripheral blood stem cell transplantation. Patients will receive a nonmyeloablative ... failed to respond adequately to conventional-dose therapy or autologous transplantation (AND) Chemoresponsive to most recent salvage therapy ...

    Clinical Trial last updated 04/29/2016 - 1:05pm.

  4. Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

    ... Background: - In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and ... at least 8 weeks after previous therapy or 12 weeks after autologous transplantation. Patients who are less than 8 weeks from ...

    Clinical Trial last updated 04/29/2016 - 1:00pm.

  5. Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

    ... to intrathecal chemotherapy . Prior allogeneic or autologous hematopoietic stem cell transplant in the last 6 months. Patients who are taking ...

    Clinical Trial last updated 06/06/2016 - 3:37pm.

  6. Total Marrow Irradiation for Refractory Acute Leukemia

    ... before a donor umbilical cord blood or hematopoietic stem cell transplant helps stop the growth of cancer cells. It may also ... Multiple myeloma No prior autologous transplant and fitting into one of the following disease categories: ...

    Clinical Trial last updated 05/02/2016 - 9:22am.

  7. Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

    ... to intrathecal chemotherapy . Prior allogeneic or autologous hematopoietic stem cell transplant in the last 6 months. Patients who are taking ...

    Clinical Trial last updated 06/03/2016 - 2:54pm.

  8. Nonmyeloablative Allogeneic Transplant (Mini-allo)

    ... Lymphoma Aggressive Histology (includes T Cell NHL) Incomplete response to induction Second CR Sensitive or ... chemotherapy or residual disease following autologous transplant) Waldenstrom Macroglobulinemia (must have failed ... Exclusion Criteria: Prior allogeneic stem cell or bone marrow transplant Current or past history of ...

    Clinical Trial last updated 04/28/2016 - 2:13pm.

  9. TCRαβ+/CD19+ Depleted Haploidentical HSCT + Zoledronate

    ... transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with ... Partial Response (VGPR) and therefore ineligible to receive autologous hematopoietic stem cell transplant (auto-HSCT) Hodgkin lymphoma ...

    Clinical Trial last updated 04/29/2016 - 4:35pm.

  10. Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106)

    ... and cyclophosphamide , the drugs used during stem cell collection and transplant, are also approved by the FDA. Melphalan is ... bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and ...

    Clinical Trial last updated 05/23/2016 - 3:45pm.